Drug Type Small molecule drug |
Synonyms AMA-0076, PHP 201, PHP-201 |
Target |
Mechanism ROCK1 inhibitors(Rho-associated protein kinase 1 inhibitors), ROCK2 inhibitors(Rho-associated protein kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization ![]() |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H18FN3O |
InChIKeyJJNXXPMAFUVGRU-UHFFFAOYSA-N |
CAS Registry934387-35-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glaucoma, Open-Angle | Phase 3 | KR | pH Pharma Co., Ltd.Startup | 01 Nov 2021 |
Low Tension Glaucoma | Phase 2 | KR | pH Pharma Co., Ltd.Startup | 06 Mar 2017 |
Glaucoma | Phase 1 | GB | 01 Sep 2013 |
Not Applicable | - | 5 | klrjvximzo(fqmqvswmzb) = Hyperemia was observed with all concentrations of Y-39983 whereas only mild hyperemia was induced after administration of AMA0076 0.4% (highest concentration used) ottjmukycl (arxhvyvhrc ) | - | 01 Jun 2013 | ||
Not Applicable | - | AMA0076 0.1% + 0.01% BAK | izwpdezean(pnvtmjplsp) = vqawjfdcat tpuwpotrkn (gvdhgwjznq ) | Positive | 01 Mar 2012 | ||
AMA0076 0.3% + 0.01% BAK | izwpdezean(pnvtmjplsp) = fytgnizdoc tpuwpotrkn (gvdhgwjznq ) |